In agreement with our previous reports in obese mice [12,14], we demonstrated that GCN2 inhibition alleviated hepatic steatosis in T2D mice, which was associated with upregulation of Acox1 and downregulation of lipid metabolic genes, including CD36, Dgat1, Fasn, Scd1, PPARγ, Cidea, and Fsp27, indicating that GCN2 inhibition repressed lipogenesis and promoted β-oxidation in the livers of T2D mice. This evidence concerns the gene PPARG and fatty liver disease.